Articles tagged with Hiv Treatments
The new guidelines, drawn from 325 studies with tens of thousands of people infected with HIV, aim to improve entry into treatment plans and adherence to lifelong drug therapy. Key strategies include systematic monitoring, patient navigators, and automated tracking systems to follow up with patients.
Research suggests that men in sub-Saharan Africa receive fewer HIV services, leading to worse health outcomes. Efforts to engage men in HIV prevention and care are crucial to addressing these disparities and ensuring a more balanced approach to gender in the fight against AIDS.
A new study suggests that immediate antiretroviral therapy (ART) is more beneficial for recently infected HIV patients than deferred treatment. The study found that participants who received ART immediately had better outcomes and were protected from disease progression not only during treatment but also after treatment was stopped.
A new study published in The New England Journal of Medicine found that the optimal time to integrate HIV treatment with TB therapy depends on a patient's immune status. Patients with advanced HIV disease who start antiretroviral treatment earlier show significant improvements in survival rates.
A mathematical model predicts that expanding HIV treatment to discordant couples in Ghana, Lesotho, Malawi, and Rwanda can prevent 96% of transmission. The intervention's effectiveness varies by country, with potential for significant impact in certain nations.
Researchers found slower disease progression among patients starting treatment with CD4 counts between 350 and 499. The study suggests initiating therapy at this range may provide long-term benefits, but no benefit is seen for patients with CD4 counts above 500.
Rapid point-of-care CD4 testing has been shown to nearly double the number of patients starting HIV treatment, while reducing dropout rates by half. This improvement is attributed to faster patient staging on-site, allowing for earlier initiation of antiretroviral therapy.
A new study suggests that adopting the World Health Organization's treatment initiation criteria for HIV-infected individuals would significantly reduce the country's HIV incidence, extend life-years, and ultimately save money. By starting ART earlier, South Africa could prevent more than 120,000 additional life-years by 2040.
A global study of real-world circumcision rollout in South Africa found a marked reduction (>60 percent) of HIV acquisition among circumcised adult men. This is the first time such a large-scale community-level intervention has shown effectiveness in curbing HIV transmission.
A study found that only about one third of patients with HIV test positive but are not yet eligible for treatment remain in care until they become eligible and start treatment. The researchers highlight the need for better health information systems to track patients between service delivery points.
Researchers stress need for long-term response to AIDS, citing financing, retention, and socio-political instability as major challenges. Social scientists urged to take part in policy-making table.
The International AIDS Society will launch a Virtual Knowledge Centre to improve knowledge and strengthened operations research capacity for HIV/OST programmes in Eastern Europe and Central Asia. The centre aims to create an increased Russian-language evidence base around OST, harm reduction, and HIV.
A large-scale study reveals that patients in Africa receiving cART for HIV can expect a near-normal lifespan, with females living longer than males. Early initiation of treatment is associated with longer life expectancy, highlighting the need for continued investment in HIV programming.
DNDi has launched a new programme to develop paediatric HIV treatments, focusing on improving dosing, tolerability and affordability. The initiative aims to fill the unmet treatment gap for millions of children with HIV/AIDS in low- and middle-income countries.
The THRIVE and ECHO phase 3 trials showed that rilpivirine is non-inferior to efavirenz with a better side-effect profile, but had a higher incidence of virological failures. Rilpivirine was found to be effective in suppressing HIV virus levels in patients starting treatment for the first time.
The success of antiretroviral-based HIV prevention, including pre-exposure prophylaxis and treatment for prevention, has transformed the landscape. Effective prevention strategies focus on implementation challenges such as HIV testing, mother-to-child transmission, and behavioural approaches.
The International AIDS Society advocates for an expanded global HIV strategy that incorporates 'Treatment as Prevention' to reduce transmission and prevent the onset of AIDS. This approach promotes widespread HIV testing and facilitated access to free treatment for all medically eligible individuals.
A new combination therapy of rifapentine and isoniazid, taken once weekly for three months, has been shown to be as effective as traditional daily treatment in preventing latent tuberculosis in people with and without HIV. The study found that 95% of participants completed the treatment, compared to 60% or less with traditional therapy.
This observational cohort study found HAART markedly improves the survival of HIV-infected children in a severely resource-deprived country. The treatment's effectiveness was comparable to that seen in more affluent settings, addressing a significant need for information on its impact in low-income countries.
China's nationwide HIV treatment coverage has increased to 63.4%, while mortality among eligible patients has fallen by 60%. However, targeting injecting drug users, those infected sexually, and men remains crucial for further improvement.
A new study by the University of California, San Francisco suggests that treating HIV-infected adults as soon as they are diagnosed can significantly reduce the rate of new HIV infections among men who have sex with men in San Francisco. This approach is expected to cut new infections by almost 60% over five years.
The European Consensus Group has developed guidelines for HIV tropism testing, which is required before starting maraviroc treatment. The guidelines recommend phenotypic enhanced sensitivity Trofile assay or V3 loop genotypic sequencing for drug-naive patients with toxic side-effects or poor tolerability.
Researchers propose engineered virus-like particles that can subdue HIV infection in individuals and spread to high-risk populations, potentially lowering the prevalence of infection. The treatment could be used in conjunction with current antiretroviral therapies or vaccine campaigns.
A study published in PLoS Medicine found that re-treatment TB regimens are failing in low- and middle-income settings, with up to one-fourth of patients experiencing relapse or death. Researchers emphasize the need for tailored treatments depending on HIV status and improved access to antiretroviral therapies.
A study in Uganda found that the standard TB retreatment regimen has low treatment response rates, particularly among HIV-infected and multi-drug resistant TB patients. Poor adherence, HIV infection, age, and duration of symptoms were associated with unsuccessful outcomes.
A new NIH study aims to determine the risks and benefits of early antiretroviral treatment in asymptomatic HIV-infected individuals with high CD4 counts. The study will compare immediate treatment to deferred treatment until CD4 counts fall below 350 cells/mm³.
A study published in PLoS Medicine found that intensive adherence counseling significantly reduces poor adherence and virologic treatment failure in patients with HIV. Patients receiving counseling were 29% less likely to experience poor adherence, and those receiving early counseling had a 59% lower risk of viral failure.
A randomized controlled trial found that intensive adherence counseling reduces poor adherence and virologic treatment failure by up to 59%. Counseling also had no significant effect on mortality or CD4 counts. The study suggests that adherence counseling should be implemented in HIV clinics caring for large numbers of patients.
A recent study found that transmitted drug-resistant (TDR) HIV significantly increases the likelihood of treatment failure, with patients more than three times as likely to experience virological failure. However, pre-treatment genotypic testing and use of ritonavir-boosted protease inhibitors can minimize this risk.
A new nomogram developed by Matthias Egger and colleagues corrects mortality rate biases in HIV treatment programs, allowing for more accurate estimates of patients lost to follow-up. This method provides a valuable tool for programmatic mortality estimates, helping to keep the HIV treatment effort on track.
The study found that earlier initiation of antiretroviral therapy increased 5-year survival from 80 to 87% and showed substantially improved early clinical outcomes. In settings where ART initiation at 350/μl is already available, switching stavudine to tenofovir offers clinical benefit and is less costly than adding second-line regimens.
Researchers found that Echinacea has no significant effect on reducing the duration or severity of cold symptoms. In contrast, a diet rich in whole-fat dairy products may help lower the risk of developing diabetes due to increased levels of trans-palmitoleate. Exercise and Vitamin D supplements are also recommended as effective interve...
A Johns Hopkins study found that delayed HIV treatment adds tens of thousands of dollars in care costs and reduces survival rates. Patients who wait too long to receive treatment require more expensive antiretroviral therapy, antibiotics, and hospitalizations.
A UCLA team is studying ways to get HIV-positive men released from LA jails into medical care and on sustained treatment. The randomized controlled trial will assess an innovative peer-navigation intervention to improve health outcomes and prevent transmission.
A new oral direct-acting antiviral drug combination has shown promising antiviral activity in patients with chronic hepatitis C. The treatment, which combines RG7128 and danoprevir, was well-tolerated and resulted in a significant reduction in viral load in some patients.
A new study found that single-dose nevirapine can hamper the drug's effectiveness if used later to treat HIV-infected women. The WHO has revised its guidelines to advise against using nevirapine in combination with other drugs, if treatment begins fewer than 12 months after exposure.
The Lancet Review emphasizes the need for tailored approaches in HIV/AIDS financing, as countries face diverging challenges. High-burden low-income (HBLI) countries will likely require extended international support, while middle-income nations with lower burdens can sustain funding using domestic resources.
A new study found that the effectiveness of anti-HIV drugs darunavir and ritonavir was similar between men and women. However, women dropped out of the trial at higher rates than men due to reasons other than drug failure. The study aims to improve retention of diverse populations in HIV treatment trials.
The PLOS Medicine editors argue for a more integrated approach to addressing HIV in maternal and child health. Concurrent crises of maternal and child health and HIV require cooperation to address effectively.
The International AIDS Society launches a new report recommending a science-based approach to scaling up treatment and prevention of HIV amongst Injecting Drug Users (IDUs). The 'Seek, test, treat and retain' model advocates for expanding outreach, testing, treatment, and retention services within the criminal justice system.
A clinical trial in Cambodia found that starting anti-HIV therapy two weeks after beginning TB treatment boosts survival rates for HIV-infected adults with weak immune systems. This approach, compared to waiting eight weeks, shows a significant difference in mortality rates among participants.
The International AIDS Conference promotes novel treatment methods, antiretroviral-based prevention options and the development of a cure. Key findings include the potential use of antiretroviral drugs to prevent infections and the need for universal access to lifesaving treatment.
The Lancet series on HIV in people who use drugs highlights the need to shift focus from individual patient adherence to health delivery conditions that create treatment interruptions. The series reports that increased ART provision to IDUs reduces infectivity and transmission, and is cost-effective.
HIV-infected drug users are at a higher risk of developing co-morbidities such as viral hepatitis, tuberculosis, and mental illness. Evidence-based treatments like medication-assisted therapies can improve treatment outcomes and reduce mortality rates.
Injecting drug users can achieve excellent virological outcomes with ART, reducing infectivity and HIV transmission. Decriminalization and law reform are crucial to overcome systemic barriers and promote equitable access to treatment.
A global survey of people living with HIV/AIDS found a significant gap in patient-physician dialogue, with discussions often lacking on chronic illnesses, treatment side effects, and co-morbid conditions. Co-morbidities like cardiovascular disease, high cholesterol, and hepatitis C are prevalent among PLWHA.
A UBC-BC CfE study found that increased HAART coverage significantly prevents HIV transmission and reduces new diagnoses in British Columbia. The expansion of HAART treatment plays a crucial role in maximizing public health resources.
A Canadian study found that the introduction of highly active antiretroviral therapy (HAART) for HIV patients in 1996 led to a significant decrease in new HIV diagnoses. The study showed that every 100 patients on HAART resulted in a 3% reduction in new HIV diagnoses.
The new guidelines recommend initiating antiretroviral treatment (ART) as soon as possible for asymptomatic individuals with low CD4+ cell counts, and treating symptomatic patients regardless of their CD4+ count. The treatment should be individualized based on concurrent conditions and previous drug exposure.
A study finds that universal HIV testing and immediate treatment could reduce new HIV infections by 15 percent, but would not halt the epidemic. The test-and-treat strategy could extend life expectancy of HIV-infected patients by one to two years.
Experts warn that failure to meet universal access pledge and budget cuts to prevention and treatment programs will deliver a major setback. Many African countries face depleting stocks of antiretroviral medications and reduced treatment coverage goals, increasing the risk of HIV drug resistance.
Increasing HAART treatment for people with HIV/AIDS lowers viral load, stops HIV progression, and prevents transmission. A comprehensive economic analysis shows expanding HAART coverage in British Columbia can deliver a net benefit of $900 million over 30 years.
The International AIDS Society calls on donors to uphold their commitment to universal access to HIV prevention, treatment, and care by 2015. Failure to do so would lead to a surge in infections, illness, and death, undermining the credibility of the G8.
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
Computer modeling and systems biology approaches can help tailor treatments to individuals, predicting disease progression and identifying host genes that affect viral development. This approach may lead to more effective treatment, detection, and prevention of future pandemics.
A new study published in the New England Journal of Medicine found that initiating antiretroviral therapy during tuberculosis treatment significantly reduces mortality rates for co-infected patients. The trial, which involved 642 patients, showed a 56% reduction in mortality rates compared to those who received sequential therapy.
Researchers from the University of Pennsylvania School of Medicine presented Phase II trial data on Lexgenleucel-T, a cell and gene therapy product for HIV treatment. The study showed 88% of evaluable subjects had a decrease in viral load set point, with one subject maintaining complete control of HIV viremia for over 14 weeks.
A new study confirms that single-dose nevirapine can lead to HIV treatment failure in women, but only if they start full antiretroviral therapy within a year after the dose. The risk of failure decreases significantly after 12 months.
A meta-analysis of 10 studies involving 1862 HIV patients found no statistically significant difference between directly observed and self-administered antiretroviral therapy in promoting virological suppression. This suggests that directly observed therapy may not be necessary to support adherence in the general patient population.
A recent study published in Academic Medicine found that medical students are commonly stuck by needles and often fail to report the injuries. The survey also showed that many medical students were reluctant to report their own safety concerns due to fears about clinical evaluations or time involved in making a report.